Fate Therapeutics (FATE) Tops Q4 EPS by 28c

Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.58), $0.28 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $44.34 million versus the consensus estimate of $17.88 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist
• After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell